Welcome to our dedicated page for Longboard Pharmaceuticals news (Ticker: LBPH), a resource for investors and traders seeking the latest updates and insights on Longboard Pharmaceuticals stock.
Longboard Pharmaceuticals, Inc. (symbol: LBPH) is a clinical-stage biopharmaceutical company dedicated to developing novel, transformative medicines aimed at treating rare neurological diseases. With a focus on optimized pharmacology and pharmacokinetics, Longboard's proprietary pipeline features multiple potentially first- or best-in-class programs that hold broad clinical utility.
The company is currently evaluating several promising drug candidates:
- LP352: A next-generation 5-HT2C agonist. This oral, centrally acting superagonist aims to treat developmental and epileptic encephalopathies (DEEs) while minimizing impact on 5-HT2B and 5-HT2A receptor subtypes.
- LP143: A centrally acting, full agonist of the cannabinoid type 2 receptor (CB2). This candidate is being developed for its potential therapeutic effects in neurological conditions.
- LP659: A highly selective, next-generation S1P receptor modulator with central action, being evaluated for its efficacy in treating neurological diseases.
Longboard Pharmaceuticals is driven by a team committed to delivering transformational medicines. The company’s focus on GPCR-targeted therapies aims to offer precise treatment options tailored to specific receptor subtypes, thereby enhancing efficacy and safety profiles. By advancing its clinical programs through rigorous scientific research and development, Longboard strives to address unmet medical needs and improve the quality of life for patients with rare neurological conditions.
Stay informed about the latest developments and updates from Longboard Pharmaceuticals, Inc. as they continue to make strides in the biopharmaceutical industry.
Rhea-AI Summary
Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH) to Host Conference Call and Webcast to Discuss Topline Data from PACIFIC Study on Bexicaserin (LP352) for Developmental and Epileptic Encephalopathies
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
316.25%
Tags
-
Rhea-AI Summary
Longboard Pharmaceuticals, a clinical-stage biopharmaceutical company (Nasdaq: LBPH), initiated a Phase 1 clinical study for LP659, a potential treatment for rare neuroinflammatory conditions. LP659 is an oral, next-generation sphingosine-1-phosphate (S1P) receptor modulator. The company plans to share Phase 1 SAD data and additional clinical plans for LP659 in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.42%
Tags
-
Rhea-AI Summary
Longboard Pharmaceuticals, Inc. (LBPH) to Present New Data for LP352 at 2023 AES Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.2%
Tags
Rhea-AI Summary
Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH) has announced the grant of inducement awards to a new employee. The Compensation Committee approved the grant of non-qualified stock options to purchase 58,520 shares of common stock at an exercise price of $5.415 per share. The stock options will vest over time based on the employee's start date and continued employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.07%
Tags
-
News
Rhea-AI Summary
Longboard Pharmaceuticals, Inc. completes enrollment for the LP352 Phase 1b/2a PACIFIC Study in August 2023. Topline data for the study is expected in January 2024. The company also plans to initiate the LP659 Phase 1 single-ascending dose (SAD) study in Q4 2023, with topline data expected in the first half of 2024. Longboard Pharmaceuticals provides a corporate update and reports financial results for Q3 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.41%
Tags
-
Rhea-AI Summary
Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH) will present at three upcoming investor conferences in November. They will present at the Guggenheim Healthcare Talks 5th Annual Inflammation, Neurology & Immunology Conference on November 7th, the Piper Sandler 35th Annual Healthcare Conference on November 29th, and the Evercore ISI HealthCONx 6th Annual Conference on November 30th. Live webcasts of the presentations will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.02%
Tags
Rhea-AI Summary
Longboard Pharmaceuticals announces speakers for its Investor & Analyst Event focused on the Developmental and Epileptic Encephalopathy (DEE) landscape and LP352
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.58%
Tags
-
Rhea-AI Summary
Longboard Pharmaceuticals to host Investor & Analyst Event on DEE landscape and LP352 development for seizure treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.27%
Tags
-
Rhea-AI Summary
Longboard Pharmaceuticals, Inc. to participate in three investor conferences in September.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.55%
Tags
Rhea-AI Summary
Longboard Pharmaceuticals will present new and encore data at the 35th International Epilepsy Congress and the American College of Clinical Pharmacology Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.86%
Tags
FAQ
What is the current stock price of Longboard Pharmaceuticals (LBPH)?
The current stock price of Longboard Pharmaceuticals (LBPH) is $59.98 as of November 29, 2024.
What is the market cap of Longboard Pharmaceuticals (LBPH)?
The market cap of Longboard Pharmaceuticals (LBPH) is approximately 2.3B.
What does Longboard Pharmaceuticals, Inc. specialize in?
Longboard Pharmaceuticals specializes in developing novel, transformative medicines for rare neurological diseases, focusing on optimized pharmacology and pharmacokinetics.
What are the key drug candidates in Longboard's pipeline?
Key drug candidates include LP352, a 5-HT2C agonist for DEEs, LP143, a CB2 receptor full agonist, and LP659, a selective S1P receptor modulator.
What is LP352?
LP352 is a next-generation 5-HT2C agonist in development for the potential treatment of developmental and epileptic encephalopathies (DEEs).
What is unique about LP143?
LP143 is a centrally acting, full agonist of the cannabinoid type 2 receptor (CB2), being developed for its therapeutic potential in neurological conditions.
What is the focus of Longboard Pharmaceuticals' research?
The focus is on developing centrally acting product candidates that are selective for specific G protein-coupled receptors (GPCRs) to treat neurological diseases.
Who can benefit from Longboard's medicines?
Patients with rare neurological diseases and conditions, such as developmental and epileptic encephalopathies, may benefit from Longboard's novel treatments.
How does Longboard ensure the safety of its treatments?
Longboard employs rigorous scientific research and development to ensure its treatments have optimized pharmacology and pharmacokinetics, aiming for high efficacy and safety.
Is Longboard Pharmaceuticals a publicly traded company?
Yes, Longboard Pharmaceuticals, Inc. is publicly traded under the stock symbol LBPH.
Where can I find the latest news about Longboard Pharmaceuticals?
You can stay informed about the latest developments and updates from Longboard Pharmaceuticals, Inc. on their official website or trusted financial news platforms like StockTitan.
What are the potential applications of LP659?
LP659 is a next-generation, highly selective S1P receptor modulator being evaluated for its potential applications in treating neurological diseases.
Longboard Pharmaceuticals, Inc.
Nasdaq:LBPH
LBPH Rankings
LBPH Stock Data
2.34B
33.87M
1.2%
121.42%
4.94%
Biotechnology
Pharmaceutical Preparations
United States of America
LA JOLLA